Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

art 1 is to explore the effect of food on the pharmacokinetics of

R7128. Preliminary data from the single ascending dose portion of the

study indicate:

-- All doses of R7128 studied were generally safe and well-tolerated.

-- All patients completed the study, and none experienced

gastrointestinal adverse events or serious adverse events during

the study.

-- No hematological or laboratory abnormalities of clinical

significance were noted.

- Part 2 is a multiple ascending dose study of R7128 conducted in 40

patients chronically infected with HCV genotype 1 who have previously

failed interferon therapy. The primary objective of Part 2 is to

assess the safety, tolerability and pharmacokinetics of R7128 after

once-daily or twice-daily dosing for 14 days. The secondary objective

is to assess antiviral activity by measuring the change in HCV RNA.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The World Health Organization estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)...  Quest Diagnostics (NYSE: DGX ), the ... that its Board of Directors has elected Jeffrey M. ... 1, 2014. Including Dr. Leiden, the Board has 11 ... and CEO of Vertex Pharmaceuticals.   Dr. Leiden has ... in the pharmaceutical and biotechnology industries as well as ...
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical ... on women,s healthcare and pain management, announced today ... The round was led by Longitude Capital ... Point Capital. Other current investors that participated in ...
... Center Association, JWCH Institute and the County of Los ... Community Health Downtown Los Angeles, a state-of-the-art medical facility ... homeless and low-income people in and around Skid Row. ... Street, is expected to meet the healthcare needs of ...
Cached Medicine Technology:Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... spike between 2008 and 2009, analysis finds , SATURDAY, ... appear to be on the rise, warns the American ... and baseball/softball are the main culprits. , The cautionary ... as they transpired between 2008 and 2009, based on ...
... drinkers were 39% less likely to get these malignancies ... help protect against head and neck cancers, a new ... the International Head and Neck Cancer Epidemiology consortium. They ... a day) were 39 percent less likely to develop ...
... is part of being a good dad, expert suggests , ... dads unwrap their new ties and other tokens of gratitude, ... kind of gift: a promise that they,ll watch their health, ... On average, men die younger than women and are more ...
... radiation not always ideal for many with low risk ... -- For patients with prostate cancer that has a ... "watchful waiting," may be a suitable treatment option, according ... of how (or whether) to treat localized prostate cancer ...
... ... ... Technologies , the leading independent provider of search software integration services announced today an ... for the Folio and NXT professional publishing products. The Folio product family includes Folio ...
... Recent research has shown increase in sexual satisfaction, if ... A U.S. Food and Drug Administration advisory panel on ... the "female Viagra" for premenopausal women with a diminished ... to the antidepressant family and affects serotonin and other ...
Cached Medicine News:Health News:Bump in Head Injury Numbers Linked to Summer Play 2Health News:On Father's Day, Give Dad Gift of Health 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 3
... Microvolume technology , The ADVIA 1650 has ... as 2 L/test), reagent consumption (as low ... L/hour) - thus maximizing management efficiency. , ... cycle and system throughput of up to ...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
Medicine Products: